Arcutis Corner is a column that will appear in every issue of JCAD NP+PA Perspectives in Dermatology in 2025. The
J Clin Aesthet Dermatol. 2025;18(3–4 Suppl 1):S12–S14. by Angelica Rose Carnemolla, BS; Eleanor Tung-Hahn, BS; Gabriela Solorzano, BS; Michael Farid,
J Clin Aesthet Dermatol. 2025;18(1–2 Suppl 1):S12–S14. by Blair Ferguson, APRN, DNP Mr. Ferguson is with Natura Dermatology and Cosmetics
J Clin Aesthet Dermatol. 2025;18(1–2 Suppl 1):S16–S20. by Douglas DiRuggiero, DMSc, MHS, PA-C, and Margaret DiRuggiero, BS, MS Dr. DiRuggiero
J Clin Aesthet Dermatol. 2025;18(1–2 Suppl 1):S36–S52. Acne Early acne improvements with fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel:
J Clin Aesthet Dermatol. 2024;17(11–12 Suppl 1):S14–S17. by Shanna M. Miranti, MPAS, PA-C Ms. Miranti is with Riverchase Dermatology and
J Clin Aesthet Dermatol. 2024;17(11-12 Suppl 1):S19–27. Acne Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel
J Clin Aesthet Dermatol. 2024;17(11–12 Suppl 1):S28 by Kasey D’Amato, PA-C, MPAP, and Kathryn Werner, PA-C Ms. D’Amato is President
J Clin Aesthet Dermatol. 2024;17(11–12 Suppl 1):S30–S33. by Miguel A. Aristizabal, MD; Tara Soto, PA-C; Leila Tolaymat, MD; and Alison
Frank Watanabe, the President and CEO of Arcutis Biotherapeutics, expresses his support for nurse practitioners and the value of their annual meeting while attending the
